1
|
Ammour Y, Nikolaeva E, Sagimbaeva O, Shamsutdinov P, Astapenko A, Zhelaeva Y, Gavrilova M, Susova O, Mitrofanov A, Bekyashev A, Nasedkina T, Svitich O, Faizuloev E, Zverev V. Human Melanoma and Glioblastoma Cells Express Cathepsins Supporting Reovirus Moscow Strain Infection. Viruses 2024; 16:1944. [PMID: 39772250 PMCID: PMC11680368 DOI: 10.3390/v16121944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2024] [Revised: 12/16/2024] [Accepted: 12/17/2024] [Indexed: 01/11/2025] Open
Abstract
This study evaluates the oncolytic potential of the Moscow strain of reovirus against human metastatic melanoma and glioblastoma cells. The Moscow strain effectively infects and replicates within human melanoma cell lines and primary glioblastoma cells, while sparing non-malignant human cells. Infection leads to the selective destruction of neoplastic cells, mediated by functional viral replication. A positive correlation was identified between viral RNA accumulation and tumor cell death, with no replication observed in non-malignant cells. This study highlights the critical roles of cathepsins B, L, and S as mediators of the oncolytic process. The pharmacological inhibition of these enzymes significantly attenuated reovirus-induced cytotoxicity in melanoma and glioblastoma cells. Conversely, PKR production analysis revealed minimal activation in reovirus-infected tumor cells, suggesting that the hyperactivation of the RAS-signaling pathway and subsequent PKR inhibition do not directly contribute to the selective efficacy of reovirus. Moreover, infected tumor cells exhibited features of both apoptotic and non-apoptotic death, emphasizing the intricate mechanisms of reovirus-mediated oncolysis. These findings underscore the therapeutic promise of the Moscow strain of reovirus as a selective and potent oncolytic agent for targeting melanoma and glioblastoma cells.
Collapse
Affiliation(s)
- Yulia Ammour
- I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia; (E.N.); (O.S.); (P.S.); (A.A.); (Y.Z.); (M.G.); (O.S.); (E.F.); (V.Z.)
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia;
| | - Eugenia Nikolaeva
- I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia; (E.N.); (O.S.); (P.S.); (A.A.); (Y.Z.); (M.G.); (O.S.); (E.F.); (V.Z.)
| | - Olesya Sagimbaeva
- I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia; (E.N.); (O.S.); (P.S.); (A.A.); (Y.Z.); (M.G.); (O.S.); (E.F.); (V.Z.)
| | - Pavel Shamsutdinov
- I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia; (E.N.); (O.S.); (P.S.); (A.A.); (Y.Z.); (M.G.); (O.S.); (E.F.); (V.Z.)
| | - Anastasia Astapenko
- I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia; (E.N.); (O.S.); (P.S.); (A.A.); (Y.Z.); (M.G.); (O.S.); (E.F.); (V.Z.)
| | - Yulia Zhelaeva
- I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia; (E.N.); (O.S.); (P.S.); (A.A.); (Y.Z.); (M.G.); (O.S.); (E.F.); (V.Z.)
| | - Marina Gavrilova
- I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia; (E.N.); (O.S.); (P.S.); (A.A.); (Y.Z.); (M.G.); (O.S.); (E.F.); (V.Z.)
| | - Olga Susova
- N.N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation, 115478 Moscow, Russia; (O.S.); (A.M.); (A.B.)
| | - Aleksey Mitrofanov
- N.N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation, 115478 Moscow, Russia; (O.S.); (A.M.); (A.B.)
| | - Ali Bekyashev
- N.N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation, 115478 Moscow, Russia; (O.S.); (A.M.); (A.B.)
| | - Tatiana Nasedkina
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia;
| | - Oxana Svitich
- I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia; (E.N.); (O.S.); (P.S.); (A.A.); (Y.Z.); (M.G.); (O.S.); (E.F.); (V.Z.)
- I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, 119146 Moscow, Russia
| | - Evgeny Faizuloev
- I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia; (E.N.); (O.S.); (P.S.); (A.A.); (Y.Z.); (M.G.); (O.S.); (E.F.); (V.Z.)
| | - Vitaly Zverev
- I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia; (E.N.); (O.S.); (P.S.); (A.A.); (Y.Z.); (M.G.); (O.S.); (E.F.); (V.Z.)
- I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, 119146 Moscow, Russia
| |
Collapse
|
2
|
Susova OY, Karshieva SS, Kostyukov AA, Moiseeva NI, Zaytseva EA, Kalabina KV, Zusinaite E, Gildemann K, Smirnov NM, Arutyunyan AF, Zhuze AL. Dimeric Bis-Benzimidazole-Pyrroles DB2Py(n) - AT-Site-Specific Ligands: Synthesis, Physicochemical Analysis, and Biological Activity. Acta Naturae 2024; 16:86-100. [PMID: 38698958 PMCID: PMC11062108 DOI: 10.32607/actanaturae.27327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2023] [Accepted: 01/29/2024] [Indexed: 05/05/2024] Open
Abstract
Its broad spectrum of biological activity makes benzimidazole a fundamental pharmacophore in pharmaceutics. The paper describes newly synthesized AT-specific fluorescent bis-benzimidazole molecules DB2Py(n) that contain a pyrrolcarboxamide fragment of the antibiotic drug netropsin. Physico-chemical methods using absorption, fluorescence, and circular dichroism spectra have shown the ability of bis-benzimidazole- pyrroles to form complexes with DNA. The new DB2Py(n) series have turned out to be more toxic to human tumor lines and less vulnerable to non-tumor cell lines. Bis-benzimidazole-pyrroles penetrated the cell nucleus, affected the cell-cycle synthesis (S) phase, and inhibited eukaryotic topoisomerase I in a cellfree model at low concentrations. A real-time tumor cell proliferation test confirmed the molecule's enhanced toxic properties upon dimerization. Preliminary cytotoxicity data for the bis-benzimidazole-pyrroles tested in a cell model with a MDR phenotype showed that monomeric compounds can overcome MDR, while dimerization weakens this ability to its intermediate values as compared to doxorubicin. In this respect, the newly synthesized cytotoxic structures seem promising for further, in-depth study of their properties and action mechanism in relation to human tumor cells, as well as for designing new AT-specific ligands.
Collapse
Affiliation(s)
- O. Y. Susova
- N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health, Moscow, 115522 Russian Federation
| | - S. S. Karshieva
- N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health, Moscow, 115522 Russian Federation
| | - A. A. Kostyukov
- Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, 119334 Russian Federation
| | - N. I. Moiseeva
- N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health, Moscow, 115522 Russian Federation
| | - E. A. Zaytseva
- N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health, Moscow, 115522 Russian Federation
| | - K. V. Kalabina
- N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health, Moscow, 115522 Russian Federation
| | - E. Zusinaite
- Tartu University Institute of Technology, Tartu, 50411 Estonia
| | - K. Gildemann
- Tartu University Institute of Technology, Tartu, 50411 Estonia
| | - N. M. Smirnov
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russian Federation
| | - A. F. Arutyunyan
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russian Federation
| | - A. L. Zhuze
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russian Federation
| |
Collapse
|
3
|
Corneillie L, Lemmens I, Weening K, De Meyer A, Van Houtte F, Tavernier J, Meuleman P. Virus-Host Protein Interaction Network of the Hepatitis E Virus ORF2-4 by Mammalian Two-Hybrid Assays. Viruses 2023; 15:2412. [PMID: 38140653 PMCID: PMC10748205 DOI: 10.3390/v15122412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 12/01/2023] [Accepted: 12/04/2023] [Indexed: 12/24/2023] Open
Abstract
Throughout their life cycle, viruses interact with cellular host factors, thereby influencing propagation, host range, cell tropism and pathogenesis. The hepatitis E virus (HEV) is an underestimated RNA virus in which knowledge of the virus-host interaction network to date is limited. Here, two related high-throughput mammalian two-hybrid approaches (MAPPIT and KISS) were used to screen for HEV-interacting host proteins. Promising hits were examined on protein function, involved pathway(s), and their relation to other viruses. We identified 37 ORF2 hits, 187 for ORF3 and 91 for ORF4. Several hits had functions in the life cycle of distinct viruses. We focused on SHARPIN and RNF5 as candidate hits for ORF3, as they are involved in the RLR-MAVS pathway and interferon (IFN) induction during viral infections. Knocking out (KO) SHARPIN and RNF5 resulted in a different IFN response upon ORF3 transfection, compared to wild-type cells. Moreover, infection was increased in SHARPIN KO cells and decreased in RNF5 KO cells. In conclusion, MAPPIT and KISS are valuable tools to study virus-host interactions, providing insights into the poorly understood HEV life cycle. We further provide evidence for two identified hits as new host factors in the HEV life cycle.
Collapse
Affiliation(s)
- Laura Corneillie
- Laboratory of Liver Infectious Diseases, Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
| | - Irma Lemmens
- VIB-UGent Center for Medical Biotechnology, Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
| | - Karin Weening
- Laboratory of Liver Infectious Diseases, Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
| | - Amse De Meyer
- Laboratory of Liver Infectious Diseases, Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
| | - Freya Van Houtte
- Laboratory of Liver Infectious Diseases, Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
| | - Jan Tavernier
- VIB-UGent Center for Medical Biotechnology, Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
| | - Philip Meuleman
- Laboratory of Liver Infectious Diseases, Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
| |
Collapse
|